High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer

E. R. Broun, G. W. Sledge, Lawrence Einhorn, G. J K Tricot

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ten patients with Stage II (four) and Stage IV (six) breast cancer were enrolled in a trial of conventional-dose induction therapy followed by high-dose therapy with autologous bone marrow support. Cyclophosphamide, methotrexate, and 5-fluorouracil were given to best response or five courses (Stage II). Those patients without progression were eligible for the high-dose portion of the protocol, which consisted of carboplatin 1500 mg/m2 and mitoxantrone at either 40 mg/m2 (first five patients) or 50 mg/m2. Two patients did not receive the high-dose portion of the treatment due to progression on induction therapy (one) and insurance refusal (one). Of the remaining eight patients who completed the high-dose portion of the protocol, three were Stage II, of whom one died of transplant-related complications, one progressed, and one is alive and free of disease 24 months after therapy. Of the five Stage IV patients, two achieved a partial remission, one of whom died of progressive disease I year after therapy and the other died of BMT-related complications; of the other three Stage IV patients, one had stable disease and died at +9 months, one with progression died at +3 months, and one died of BMT-related causes. Overall, three patients died of infectious complications, with two having alpha streptococcal septic shock syndrome.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number1
StatePublished - 1993

Fingerprint

Mitoxantrone
Carboplatin
Bone Marrow
Breast Neoplasms
Therapeutics
Septic Shock
Insurance
Methotrexate
Fluorouracil
Cyclophosphamide
Transplants

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer. / Broun, E. R.; Sledge, G. W.; Einhorn, Lawrence; Tricot, G. J K.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 16, No. 1, 1993, p. 9-13.

Research output: Contribution to journalArticle

@article{3fbf184a11694643b6608ad4bd6fcb5f,
title = "High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer",
abstract = "Ten patients with Stage II (four) and Stage IV (six) breast cancer were enrolled in a trial of conventional-dose induction therapy followed by high-dose therapy with autologous bone marrow support. Cyclophosphamide, methotrexate, and 5-fluorouracil were given to best response or five courses (Stage II). Those patients without progression were eligible for the high-dose portion of the protocol, which consisted of carboplatin 1500 mg/m2 and mitoxantrone at either 40 mg/m2 (first five patients) or 50 mg/m2. Two patients did not receive the high-dose portion of the treatment due to progression on induction therapy (one) and insurance refusal (one). Of the remaining eight patients who completed the high-dose portion of the protocol, three were Stage II, of whom one died of transplant-related complications, one progressed, and one is alive and free of disease 24 months after therapy. Of the five Stage IV patients, two achieved a partial remission, one of whom died of progressive disease I year after therapy and the other died of BMT-related complications; of the other three Stage IV patients, one had stable disease and died at +9 months, one with progression died at +3 months, and one died of BMT-related causes. Overall, three patients died of infectious complications, with two having alpha streptococcal septic shock syndrome.",
author = "Broun, {E. R.} and Sledge, {G. W.} and Lawrence Einhorn and Tricot, {G. J K}",
year = "1993",
language = "English",
volume = "16",
pages = "9--13",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer

AU - Broun, E. R.

AU - Sledge, G. W.

AU - Einhorn, Lawrence

AU - Tricot, G. J K

PY - 1993

Y1 - 1993

N2 - Ten patients with Stage II (four) and Stage IV (six) breast cancer were enrolled in a trial of conventional-dose induction therapy followed by high-dose therapy with autologous bone marrow support. Cyclophosphamide, methotrexate, and 5-fluorouracil were given to best response or five courses (Stage II). Those patients without progression were eligible for the high-dose portion of the protocol, which consisted of carboplatin 1500 mg/m2 and mitoxantrone at either 40 mg/m2 (first five patients) or 50 mg/m2. Two patients did not receive the high-dose portion of the treatment due to progression on induction therapy (one) and insurance refusal (one). Of the remaining eight patients who completed the high-dose portion of the protocol, three were Stage II, of whom one died of transplant-related complications, one progressed, and one is alive and free of disease 24 months after therapy. Of the five Stage IV patients, two achieved a partial remission, one of whom died of progressive disease I year after therapy and the other died of BMT-related complications; of the other three Stage IV patients, one had stable disease and died at +9 months, one with progression died at +3 months, and one died of BMT-related causes. Overall, three patients died of infectious complications, with two having alpha streptococcal septic shock syndrome.

AB - Ten patients with Stage II (four) and Stage IV (six) breast cancer were enrolled in a trial of conventional-dose induction therapy followed by high-dose therapy with autologous bone marrow support. Cyclophosphamide, methotrexate, and 5-fluorouracil were given to best response or five courses (Stage II). Those patients without progression were eligible for the high-dose portion of the protocol, which consisted of carboplatin 1500 mg/m2 and mitoxantrone at either 40 mg/m2 (first five patients) or 50 mg/m2. Two patients did not receive the high-dose portion of the treatment due to progression on induction therapy (one) and insurance refusal (one). Of the remaining eight patients who completed the high-dose portion of the protocol, three were Stage II, of whom one died of transplant-related complications, one progressed, and one is alive and free of disease 24 months after therapy. Of the five Stage IV patients, two achieved a partial remission, one of whom died of progressive disease I year after therapy and the other died of BMT-related complications; of the other three Stage IV patients, one had stable disease and died at +9 months, one with progression died at +3 months, and one died of BMT-related causes. Overall, three patients died of infectious complications, with two having alpha streptococcal septic shock syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0027509482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027509482&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 9

EP - 13

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -